52P Modified FOLFIRINOX versus CISGEM as first-line chemotherapy for advanced biliary tract cancer: Results of AMEBICA PRODIGE 38 randomized phase II trial
Jean–Marc Phelip, Jérôme Desrame, Julien Edeline, Emilie Barbier, Eric Terrebonne, Pierre Michel, Hervé Perrier, Laëtitia Dahan, Vincent Bourgeois, F. Khemissa Akouz, Émilie Soularue, V. Lebrun, Yann Molin, Thierry Lecomte, François Ghiringhelli, Romain Coriat, Samy Louafi, Cindy Neuzillet, Sylvain Manfrédi, David Malka
Topics & Concepts
MedicineFOLFIRINOXGemcitabineClinical endpointInternal medicinePhases of clinical researchChemotherapyGastroenterologyRandomized controlled trialSurgeryIrinotecanCancerColorectal cancerCholangiocarcinoma and Gallbladder Cancer StudiesPhytase and its ApplicationsOral and gingival health research